A Phase 3, Multicentre, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
This is an international, multicentre, open-label, randomized, Phase 3 study comparing the
efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years
or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or
third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society